Research - PRGF®-Endoret®

Regenerative medicine and biological therapies offer new solutions every day in many areas of healthcare, such as dentistry, orthopedics, ophthalmology, dermatology and clinical aesthetics. In the field of anti-aging treatments and facial rejuvination the technique of PRGF®-Endoret®, (Plasma Rich in Growth Factors) has proven to be one of the safest, most effective and lasting treatments available today to significantly delay the signs of aging.

PRGF®-Endoret® is the result of intensive research and development carried out by the scientific team at BTI Biotechnology Institute.

The efficacy and safety of this technique is supported by more than 15 years of research in tissue regeneration by BTI, by the large number of clinical trials carried out successfully and the recognition of the international
scientific community. Furthermore, over half a million patients have been treated with PRGF®-Endoret® technology without a single adverse outcome reported. Among all patients treated are athletes and relevant media personalities.

Warrantly and reliability

PRGF®-Endoret® technology is one of the few techniques with European CE Certifications for each of the following applications

About PRGF

  • Dental Implant Systems and Treatment
  • Regeneration Of Cornial Lesions (Eyes)
  • Healing of Ulcers
  • Consolidation of Bone Fractures and Grafts
  • Injuries to Locomotor System (muscles, tendons, ligaments, joints, etc)
  • Fixation of Prosthesis (hip, knee, etc)


Since 1999, PRGF®-Endoret® is the first technique to obtain an autologous concentrate of growth factors (from a small amount of the patient’s own blood) with worldwide recognition and patented by BTI Biotechnology Institute.